Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
22 studies found for:    "methodist hospital" | Open Studies | "Breast Neoplasms" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: TDM1;   Drug: Lapatinib;   Drug: Abraxane
2 Recruiting Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)
Conditions: Breast Neoplasms;   Breast Cancer
Interventions: Drug: Taxane;   Drug: Taxotere;   Drug: Abraxane;   Drug: Ixabepilone
3 Recruiting L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Drug: L-NMMA;   Drug: Docetaxel;   Drug: Amlodipine;   Drug: Pegfilgrastim
4 Recruiting Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Hydroxytyrosol
5 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
6 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel;   Drug: Pertuzumab
7 Recruiting Multi-scale Modeling of Breast Conserving Therapy
Condition: Breast Cancer
Intervention: Other: Standard of Care
8 Recruiting TAA-Specific CTLS for Solid Tumors (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
9 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
10 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
11 Recruiting A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Condition: HER2+ Metastatic Breast Cancer (MBC)
Interventions: Drug: neratinib;   Drug: capecitabine;   Drug: lapatinib
12 Recruiting Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Conditions: Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
13 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
Interventions: Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
14 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
15 Recruiting Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Conditions: Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
16 Recruiting A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: paclitaxel;   Drug: Reparixin;   Drug: placebo
17 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole
18 Recruiting Breast Cancer WEight Loss Study (BWEL Study)
Conditions: Ductal Breast Carcinoma in Situ;   Breast Carcinoma
Interventions: Other: Health Education Program;   Other: Weight Loss Intervention
19 Recruiting Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole;   Drug: BYL719
20 Recruiting Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.